Prostate apoptosis response-4 (Par-4) is a tumor suppressor which protects against neoplastic transformation. Remarkably, Par-4 is capable of inducing apoptosis selectively in cancer cells without affecting the normal cells. In this study, we found that recombinant Par-4 protein had limited serum persistence in mice that may diminish its anti-tumor activity in vivo. To improve the in vivo performance of the short-lived Par-4 protein, we aimed to develop a novel, long-lasting form of Par-4 with extended sequence, denoted as Par-4Ex, without affecting the desirable molecular function of the natural Par-4. We demonstrate that the Par-4Ex protein entity, produced by using the Escherichia coli expression system suitable for large-scale production, fully retains the desirable pro-apoptotic activity of Par-4 protein, but with ~7-fold improved biological half-life. Further in vivo tests confirmed that, due to the prolonged biological half-life, the Par-4Ex protein is indeed more potent in suppressing metastatic tumor growth in mice.
|Number of pages||8|
|Journal||Protein Engineering, Design and Selection|
|State||Published - Dec 13 2019|
Bibliographical notePublisher Copyright:
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: firstname.lastname@example.org.
- biological half-life
- metastatic cancer
- protein engineering
- therapeutic protein
ASJC Scopus subject areas
- Molecular Biology